The new therapy may prove to be an effective foe against prostate cancer. A new study by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy shows promise for a monoclonal antibody, enoblituzumab, as a safe and potentially effective immunotherapy agent against prostate cancer.